A5075208609- Cannabis and Cannabinoid Research
- Neuroscience and Neuropharmacology Research
- Neurotransmitter Receptor Influence on Behavior
- Epilepsy research and treatment
- Drug Transport and Resistance Mechanisms
- Sleep and Wakefulness Research
- Tryptophan and brain disorders
- Psychedelics and Drug Studies
- Stress Responses and Cortisol
- Pancreatic function and diabetes
- Neuroendocrine regulation and behavior
- Forensic Toxicology and Drug Analysis
- Prenatal Substance Exposure Effects
- GABA and Rice Research
- Bipolar Disorder and Treatment
- Ion channel regulation and function
- Neuroscience of respiration and sleep
- Diet, Metabolism, and Disease
- Amino Acid Enzymes and Metabolism
- Substance Abuse Treatment and Outcomes
- Homelessness and Social Issues
- Advanced MRI Techniques and Applications
- Genetics and Neurodevelopmental Disorders
- Sleep and related disorders
- Heart Failure Treatment and Management
The University of Sydney
2016-2025
Swinburne University of Technology
2024
National Institute of Integrative Medicine
2022
Endeavour College of Natural Health
2019
Western Sydney University
2017
Robert Bosch (Australia)
2007-2017
Camden and Campbelltown Hospitals
2017
Sax Institute
2016
MIND Research Institute
2010-2013
Schizophrenia Research Institute
2007-2013
Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing schizophrenia. The behavioural profiles the psychotropic cannabis constituent Δ9-tetrahydrocannabinol (Δ9-THC) non-psychotomimetic cannabidiol (CBD) were investigated with a battery tests relevant anxiety positive, negative cognitive symptoms Male adult C57BL/6JArc mice given 21 daily intraperitoneal injections vehicle, Δ9-THC (0.3, 1, 3 or 10 mg/kg) CBD (1, 5, 50 mg/kg). produced classic...
Recent analysis of the cannabinoid content cannabis plants suggests a shift towards use high potency plant material with levels Δ9-tetrahydrocannabinol (THC) and low other phytocannabinoids, particularly cannabidiol (CBD). Use this type is thought by some to predispose greater adverse outcomes on mental health fewer therapeutic benefits. Australia has one highest per capita rates in world yet there been no previous systematic being used. In present study we examined 206 samples that had...
Previous studies have suggested that administration of oxytocin (OT) can modulatory effects on social and anxiety-like behavior in mammals may endure beyond the time acute OT administration. The current study examined whether repeated to male Wistar rats (n = 48) during a key developmental epoch (early adolescence) altered their physiology later-life. Group housed were given intraperitoneal injections either 1 mg/kg or vehicle early adolescence (post natal-days [PND] 33–42). treatment caused...
Abstract Objective Cannabidiol ( CBD ) has been approved by the US Food and Drug Administration (FDA) to treat intractable childhood epilepsies, such as Dravet syndrome Lennox‐Gastaut syndrome. However, intrinsic anticonvulsant activity of questioned due a pharmacokinetic interaction between first‐line medication, clobazam. This recognized led speculation that efficacy may simply reflect augmenting clobazam exposure. The present study aimed address nature Methods We examined whether inhibits...
ABSTRACT Recent preclinical evidence indicates that the neuropeptide oxytocin may have potential in treatment of drug dependence and withdrawal. Oxytocin reduces methamphetamine self‐administration, conditioned place preference hyperactivity rodents. However, it is unclear how acts brain to produce such effects. The present study examined patterns neural activation produced by were modified co‐administered oxytocin. Male Sprague‐Dawley rats pretreated with either 2 mg/kg (IP) or saline then...
In 2016, the Australian federal government passed legislation enabling a range of cannabis-based products to be prescribed patients by registered healthcare professionals. An online survey conducted immediately prior these legislative changes found that vast majority respondents at time were illicitly sourcing cannabis plant matter, smoking was preferred route administration and mental health, chronic pain, sleep conditions most frequently cited reasons for medical use. This manuscript...
Introduction: Compounds present in Cannabis sativa such as phytocannabinoids and terpenoids may act concert to elicit therapeutic effects. Cannabinoids Δ9-tetrahydrocannabinol (Δ9-THC) directly activate cannabinoid receptor 1 (CB1) 2 (CB2); however, it is not known if also affect signaling. Therefore, we examined six common alone, combination with agonists, on CB1 CB2 signaling vitro. Materials Methods: Potassium channel activity AtT20 FlpIn cells transfected human or receptors was measured...
Cannabis sativa produces a complex mixture of many bioactive molecules including terpenophenolic compounds known as phytocannabinoids. Phytocannabinoids come in neutral forms (e.g., Δ9-tetrahydrocannabinol, THC; cannabidiol, CBD; etc.) or acid precursors, which are dominant the plant Δ9-tetrahydrocannabinolic acid, THCA; cannabidiolic CBDA; etc.). There is increasing interest unlocking therapeutic applications phytocannabinoid acids; however, present understanding basic pharmacology acids...
Recent legislative change has allowed increased access to cannabis products in many jurisdictions. In some locations, this includes over-the-counter (OTC) and/or online containing cannabidiol (CBD), a non-intoxicating cannabinoid with therapeutic properties. Here we compared the availability of CBD and associated regulatory background nine selected countries. Accessibility was examined USA, Canada, Germany, Ireland, United Kingdom, Switzerland, Japan, Australia, New Zealand as May 2020....
Abstract Background Australia has had a framework for legal medicinal cannabis since 2016, yet prior online surveys in 2016 and 2018 indicated that most consumers continued to use illicit medical products. Regulatory data indicate an increase the prescription of 2019, this survey examines consumer experiences prescribed (MC) Australia. Methods A cross-sectional anonymous was administered September 2020 January 2021. Recruitment via social media, professional forums, practices. Participant...
Background and purpose: Cannabinoids are used therapeutically for the palliation of adverse side effects associated with cancer chemotherapy. However, cannabinoids also inhibit both activity expression multidrug transporter, P‐glycoprotein in vitro . Here we address interaction cannabinol (CBN), cannabidiol (CBD) Δ 9 ‐tetrahydrocannabinol (THC) related ABCG2. Experimental approach: Cannabinoid inhibition Abcg2/ABCG2 was assessed using flow cytometric analysis substrate accumulation ATPase...
The cannabis constituent cannabidiol (CBD) possesses anxiolytic and antipsychotic properties. We have previously shown that transmembrane domain neuregulin 1 mutant (Nrg1 TM HET) mice display altered neurobehavioural responses to the main psychoactive of cannabis, Δ9-tetrahydrocannabinol. Here we investigated whether Nrg1 HET respond differently CBD reverses schizophrenia-related phenotypes expressed by these mice. Adult male wild type-like littermates (WT) received vehicle or (1, 50 100...
Abstract Heavy cannabis abuse increases the risk of developing schizophrenia. Adolescents appear particularly vulnerable to development psychosis-like symptoms after use. To test whether schizophrenia candidate gene neuregulin 1 (NRG1) modulates effects cannabinoids in adolescence, we tested male adolescent heterozygous transmembrane domain Nrg1 mutant (Nrg1 TM HET) mice and wild type-like littermates (WT) for their neurobehavioural response repeated Δ9-tetrahydrocannabinol (THC, 10 mg/kg...